BioSpace News Archive

Noveome Biotherapeutics, Inc., Pittsburgh, PA, and SipNose, Ltd., Yokneam, Israel, announced today that they have entered into a Commercial License Agreement (“Agreement”) for Noveome’s use of SipNose’s proprietary intranasal Cribriform Targeted Device (CT6) to deliver Noveome’s first-of-its-kind biologic, ST266, to the central nervous system (CNS).

New Orders, Production & Employment Growing; Supplier Deliveries Slowing at Faster Rate; Backlog Growing; Raw Materials Inventories Growing; Customers’ Inventories Too Low; Prices Increasing; Exports and Imports Growing

HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, today announced that the first patient has been dosed in HighTide’s Phase 2 PRONTO-PBC study evaluating first-in-class HTD1801 in adult patients with primary biliary cholangitis (PBC).

VirtaMed, the world leader in medical simulation training, has added Andy Weymann to its board of directors.

Puyi (Shanghai) Biotechnology Co., Ltd. (“Puyi Biotechnology”) recently announced the completion of its Series B financing led by Goldman Sachs Asset Management.

Cleveland Clinic’s Weston Hospital has performed its first living donor liver transplant, in which a daughter donated a portion of her liver to her mother who had been battling complicated liver disease for several years.

Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures announced that management will participate in two investor conference events during the month of June 2021.

The Company’s highest priority is to create shareholder value through the development and commercialization of products and delivery technology.

Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 4th to 8th. The first trial